Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)

NCT03292809 is registered in ClinicalTrials.gov with Novaliq GmbH as lead sponsor.

NCT NCT03292809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03292809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Lead sponsor
Novaliq GmbH
Phase
Phase 2/3
Overall status
Completed
Start date
October 19, 2017
Completion date
June 20, 2018
Enrollment
328 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease